UC San Diego Center for Transplantation “VAD Destination Therapy” Approved

Heart failure patients with few options find future in mechanical devices

The Joint Commission has approved UC San Diego Health System’s Disease-Specific Care Certification for Ventricular Assist Device (VAD). Hospitals performing VAD as a “destination therapy” (for permanent use) receive a certification of distinction and receive reimbursement from Centers for Medicare and Medicaid Services… Read the full story from the UCSD Newsroom


Co-directing the VAD program is Eric Adler, MD, Health Sciences Associate Clinical Professor in the Division of Cardiology. Dr. Adler co-directs the Ventricular Assist Devices program with Jack Copeland, MD, at the UCSD Sulpizio Cardiovascular Center (pictured above).

UCSD Opens Clinical Trial of Gene Therapy Drug for Advanced Heart Failure

UCSD Medical Center investigators are enrolling patients in a Phase 2 clinical trial of MYDICAR®, a new gene therapy for advanced heart failure.

The drug is designed to boost the efficiency of the heart by restoring a crucial heart enzyme.

UCSD cardiologist Dr. Barry H. Greenberg is principal investigator of the UCSD portion of the study, which is known as the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial.

In all, 13 centers are participating.

Dr. Greenberg is Professor of Medicine in the Division of Cardiology and director of the Advanced Heart Failure Treatment Program at UCSD Medical Center. He is the founder and current president of the Heart Failure Society of America.

Read the full story from UC San Diego Health Sciences Communications

More Information:

UCSD Nephrology Teaming with University of Alabama in O’Brien Center Grant

The Division of Nephrology in UC San Diego’s Department of Medicine has become part of a prestigious national kidney research network with the award of a five-year, $4.23 million O’Brien Research Center grant to the University of Alabama at Birmingham (UAB).

The project, which will bring about $400,000 annually to UCSD, will focus on finding new ways to prevent and to treat kidney failure.

Read the full story
from Health Sciences Communications

UCSD nephrologists, headed by Ravindra L. Mehta, M.D., F.A.C.P., will operate one of the core research efforts in the UAB/UCSD O’Brien Center.

Dr. Mehta, professor of clinical medicine in the Division of Nephrology, is Associate Chair for Clinical Affairs in the Department of Medicine.

Two other UCSD Nephrology researchers will contribute their research expertise in genetics and molecular markers of kidney injury:

The O’Brien Center funding comes from the National Institute of Diabetes and Digestive and Kidney Diseases. There are only eight O’Brien kidney research centers in the United States.

More Information: